Beacon Therapeutics Overview
- Status
-
Private
- Employees
-
95
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$75.2M
- Investors
-
8
Beacon Therapeutics General Information
Description
Operator of a clinical-stage biotechnology company intended to treat patients with rare lung and eye diseases. The company utilizes a proprietary gene therapy platform to develop transformational genetic therapies for patients with rare and debilitating diseases, with a focus on ophthalmology, enabling clinicians to improve the lives of patients with severe conditions significantly.
Contact Information
Website
www.beacontx.comCorporate Office
- Rolling Stock Yard, 2nd floor
- 188 York Way, Kings Cross
- London N7 9AS
- England, United Kingdom
Corporate Office
- Rolling Stock Yard, 2nd floor
- 188 York Way, Kings Cross
- London N7 9AS
- England, United Kingdom
Beacon Therapeutics Timeline
Beacon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 09-Jan-2026 | $75.2M | Completed | Clinical Trials - Phase 3 | ||
| 3. Early Stage VC (Series B) | 03-Jul-2024 | Completed | Clinical Trials - Phase 3 | |||
| 2. Early Stage VC (Series A) | 12-Jun-2023 | $119M | $119M | Completed | Clinical Trials - Phase 3 | |
| 1. Accelerator/Incubator | 01-Mar-2023 | Completed | Startup |
Beacon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C Preferred | ||||||||
| Series B3 Preferred | ||||||||
| Series B2 Preferred | ||||||||
| Series B1 Preferred | ||||||||
| Series A Preferred | ||||||||
| Ordinary | 11,103,867 | $0.000013 | $1.34 | $1.34 | 1x | $1.34 | 4.52% | |
| Ordinary | 48,796,133 | $0.000013 | $1.11 | $1.11 | 1x | $1.11 | 19.86% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Beacon Therapeutics Comparisons
Industry
Financing
Details
Beacon Therapeutics Competitors (3)
One of Beacon Therapeutics’s 3 competitors is SparingVision, a Venture Capital-Backed company based in Paris, France.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SparingVision | Venture Capital-Backed | Paris, France | ||||
| GenSight Biologics | Formerly VC-backed | Paris, France | ||||
| Coave Therapeutics | Venture Capital-Backed | Paris, France |
Beacon Therapeutics Signals
Beacon Therapeutics Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Goldman Sachs Asset Management | Asset Manager | Minority | ||
| Retinal Degeneration Fund | Not-For-Profit Venture Capital | Minority | ||
| Advent Life Sciences | Venture Capital | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Oxford Science Enterprises | Venture Capital | Minority |
Beacon Therapeutics Acquisitions (1)
Beacon Therapeutics’s most recent deal was a Merger/Acquisition with Applied Genetic Technologies. The deal was made on 01-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Applied Genetic Technologies | 01-Dec-2022 | Merger/Acquisition | Drug Discovery |
Beacon Therapeutics FAQs
-
Where is Beacon Therapeutics headquartered?
Beacon Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Beacon Therapeutics?
Beacon Therapeutics has 95 total employees.
-
What industry is Beacon Therapeutics in?
Beacon Therapeutics’s primary industry is Drug Discovery.
-
Is Beacon Therapeutics a private or public company?
Beacon Therapeutics is a Private company.
-
What is the current valuation of Beacon Therapeutics?
The current valuation of Beacon Therapeutics is .
-
What is Beacon Therapeutics’s current revenue?
The current revenue for Beacon Therapeutics is .
-
How much funding has Beacon Therapeutics raised over time?
Beacon Therapeutics has raised $362M.
-
Who are Beacon Therapeutics’s investors?
Goldman Sachs Asset Management, Retinal Degeneration Fund, Advent Life Sciences, Forbion, and Oxford Science Enterprises are 5 of 8 investors who have invested in Beacon Therapeutics.
-
Who are Beacon Therapeutics’s competitors?
SparingVision, GenSight Biologics, and Coave Therapeutics are competitors of Beacon Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process